INCLINE VILLAGE, Nev., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Tri Pointe Homes® (NYSE: TPH), one of the largest homebuilders in the U.S., announced today that it has earned coveted inclusion on the 2024 PEOPLE® Companies That Care® list from PEOPLE Magazine and Great Place To Work® and the 2024 Fortune Best Workplaces in Construction™ List from Fortune magazine and Great Place to Work®. The accolades reflect Tri Pointe’s ongoing dedication to fostering a workplace culture that prioritizes care, innovation, and ...

Accolade (ACCD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a chan ...

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5 at 9:15 am ET. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. About Accolade, Inc. Accolade (Nasdaq: ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live ...

LITTLE ROCK, Ark., Aug. 22, 2024 /PRNewswire/ -- Celeste Health Solutions (Celeste), a new company that will focus on merging the power of data insights, technology and personalized health management, is being introduced to the market to simplify healthcare access for employees while also easing the burden for employers.According to Bryan Dorathy, Celeste's Vice President of Innovation, Celeste will appeal to employers who want to see their employees' health improve while also helping them better navigate t ...

文章核心观点 - Accolade (ACCD)股价最近遭受过度抛售压力,股价在过去4周内下跌47% [1] - 但该股目前已进入超卖区域,华尔街分析师预计公司将报告优于此前预期的盈利 [1] 公司情况总结 - Accolade (ACCD)股价最近遭受过度抛售压力,股价在过去4周内下跌47% [1] - 该股目前RSI读数为19.38,已进入超卖区域,表明股价下跌趋势可能即将反转 [2] - 分析师对该公司当前年度的盈利预测在过去30天内上调了5.1% [3] - 该公司目前被评为Zacks Rank 2(买入),表明其短期内有望出现反弹 [3]

Accolade (ACCD) has been on a downward spiral lately with significant selling pressure. After declining 47% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is ove ...

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. (“Accolade” or “the Company”) (NASDAQ: ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ACCD. Investigation Details On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share. Following its earnings re ...

ipopba Elevator Pitch I have a Hold investment rating for Accolade, Inc. (NASDAQ:ACCD) stock. My prior April 5, 2024 write-up drew attention to Accolade's latest corporate developments like the addition of new partners. The current update reviews ACCD's Q1 FY 2025 (YE February 28, 2025) financial performance and evaluates the company's financial prospects. Accolade's Q1 results benefited from a favorable timing difference, but its updated full-year guidance was mixed. ACCD lowered its FY 2025 top line guida ...

财务数据和关键指标变化 - 第一季度收入约为1.105亿美元,同比增长18% [15] - 调整后EBITDA亏损330万美元 [16] - 调整后毛利率提升至47.8%,去年同期为43.5% [16] - 现金、现金等价物和有价证券总额为2.31亿美元 [17] 各条业务线数据和关键指标变化 - 直接面向消费者的PlushCare业务预计今年增长约20%,增速略低于之前预期 [20][21] - 基于平台的Expert Medical Opinion和企业级虚拟初级护理业务将继续快于整体业务增长 [22] 各个市场数据和关键指标变化 - 总体需求环境保持强劲,公司在本年度早期阶段已签署了一笔数百万美元的服务合同 [23] - 公司将保持定价和利润率方面的纪律,不会为了追求业务而牺牲利润 [23] 公司战略和发展方向及行业竞争 - 公司选择智能、有利可图的增长和确定的底线,这种方法可为客户、员工、合作伙伴和股东带来最大价值 [27][28][29] - 公司将继续投资人工智能、紧密集成的产品以及市场领先的临床质量和能力 [30] - 公司目前拥有1200多家客户和1400万会员,2000多名员工致力于为客户和会员提供更好的医疗体验 [30] - 公司在过去15年中建立了业务,未来也将继续发挥这一优势 [30] 管理层对经营环境和未来前景的评论 - 公司选择智能、有利可图的增长和确定的底线,以应对当前的市场因素和对可靠的底线收益预测的需求 [8][9][19] - 公司将收紧一些营销支出,专注于最有利可图的机会,以确保实现利润目标 [20][21][22][24] - 公司将保持定价和利润率方面的纪律,不会为了追求业务而牺牲利润 [23] - 公司认为,在新兴市场中,专注于客户、采取可扩展的盈利策略的公司最终将成为赢家 [12] 其他重要信息 - 公司将在今年晚些时候举行分析师日,届时将提供更多关于长期计划的细节 [10] - 公司认为,个性化医疗保健建立在有效平台之上的类别已在市场上得到很好的确立,需求持续强劲 [11] 问答环节重要的提问和回答 问题1 **Richard Close 提问** 提问了关于收入指引下调的3个主要原因 [32] **Rajeev Singh 和 Steve Barnes 回答** 1) 公司选择适度收紧收入指引,以确保实现利润目标 [33][34][35][36][37][38][39][40][41] 2) 公司将收紧一些营销支出,专注于最有利可图的机会 [38][39][40][41][42] 3) 公司将保持定价和利润率方面的纪律,不会为了追求业务而牺牲利润 [41][42][43] 问题2 **Craig Hettenbach 提问** 提问了关于基于使用的收入以及核心业务咨询服务的增长预期 [44] **Steve Barnes 回答** 1) 公司对基于使用的收入有较好的可见性,预计将继续快于整体业务增长 [45][46][47] 2) 咨询服务业务的年度经常性收入(ARR)过去2年增长20%-30%,今年增长前景乐观 [47] 问题3 **Michael Cherny 提问** 提问了关于本季度收入超预期以及全年收入指引下调的具体原因 [49] **Steve Barnes 回答** 1) 收入指引下调主要是由于基于使用的收入和直接面向消费者的PlushCare业务收入下调 [51][52][53] 2) 这些收入下调主要是为了控制相关营销支出,以确保利润目标 [51][52][53]

Accolade (ACCD) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.52 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 27.08%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.10, delivering a surprise of 9.09%. Over the last four quarters, the company has surpassed cons ...